Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality8/10

Cryoport lifts 2026 revenue guidance on CGT momentum and trials

Nov 5, 2026, 4:13 PM EST1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Guidance upgrade, sustained CGT momentum, and a positive near-term EBITDA signal are price-relevant catalysts likely to drive a positive re-rating in the near term, despite ongoing net losses.

AI summary

What happened, with direct paths to the underlying reporting

Cryoport posted Q3 revenue of $50.2 million, up 14% YoY, with CGT revenue up 20% and BioStorage/BioServices up 25%. The company raised full-year 2026 revenue guidance to $197–$199 million and reported positive adjusted EBITDA of $1.1 million, underscoring progress toward profitability amid expanding CGT demand and a record 788 trials across 23 therapies.

Q3 revenue $50.2M, up 14% YoY; CGT revenue +20%.
23 commercial CGT therapies supported; 788 global trials; 99 in Phase 3.
9M 2026 revenue $146.99M, +12% YoY; Life Sciences Services up 18%.
Guidance raised to $197–$199M for 2026; Adj EBITDA $1.1M in Q3.
Cash & equivalents $393.1M as of 9/30/2026; solid liquidity.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.